WebCooper O, Parmar M, Isacson O. Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy. Prog. Brain Res. 2012; 200:265-76. PubMed. Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, Glatt CE, Isacson O. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine … WebDr. Isacson brings extensive medical and scientific insight with a deep understanding of central nervous system (CNS) diseases, and experience leading the R&D function of a …

Pfizer Appoints Chief Scientific Officer for Neuroscience Research

WebSource: Ole Isacson via Europe PubMed Central α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiology of disease … WebOle Isacson Loss-of-function mutations in GBA1 are a genetic risk factor for the α-synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy Bodies. in flight training

Ole Isacson, MD, PhD Parkinson

WebOle Isacson, MD, is a professor of neurology and neuroscience at Harvard Medical School, a principal faculty member at the Harvard Stem Cell Institute, and is the Founding Director of the Neuroregeneration Research Institute at McLean Hospital/Harvard Medical School. He received undergraduate, doctoral, and medical degrees from the University ... WebOle Isacson Ole Isacson. Professor of Neurology. The goal of our laboratory is to prevent the causes of brain degeneration and loss of neuronal function. In addition, we aim to … WebIn 2024, Ole Isacson co-founded Oryon Cell Therapies Inc. with Nikola Kojic. Prof. Isacson is the author or co-author of ~ 400 scientific research articles and 3 books in his field, and the Editor-in-Chief of Molecular and Cellular Neuroscience (2010-2016). Prof. Isacson was elected fellow of the American Association for the Advancement of ... in flight tracking map